HomeCompareCYAD vs QSR

CYAD vs QSR: Dividend Comparison 2026

CYAD yields 425.53% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYAD wins by $18058.57M in total portfolio value
10 years
CYAD
CYAD
● Live price
425.53%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18058.60M
Annual income
$12,349,610,253.13
Full CYAD calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — CYAD vs QSR

📍 CYAD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYADQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYAD + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYAD pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYAD
Annual income on $10K today (after 15% tax)
$36,170.21/yr
After 10yr DRIP, annual income (after tax)
$10,497,168,715.16/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, CYAD beats the other by $10,497,168,385.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYAD + QSR for your $10,000?

CYAD: 50%QSR: 50%
100% QSR50/50100% CYAD
Portfolio after 10yr
$9029.31M
Annual income
$6,174,805,320.50/yr
Blended yield
68.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

CYAD
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
-41.9
Piotroski
2/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYAD buys
0
QSR buys
0
No recent congressional trades found for CYAD or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYADQSR
Forward yield425.53%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$18058.60M$24.7K
Annual income after 10y$12,349,610,253.13$387.88
Total dividends collected$17541.95M$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusBuyBuy

Year-by-year: CYAD vs QSR ($10,000, DRIP)

YearCYAD PortfolioCYAD Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$53,253$42,553.19$11,038$337.57+$42.2KCYAD
2$268,765$211,784.42$12,156$345.43+$256.6KCYAD
3$1,286,515$998,936.38$13,359$352.69+$1.27MCYAD
4$5,845,421$4,468,849.76$14,654$359.36+$5.83MCYAD
5$25,230,957$18,976,356.52$16,045$365.45+$25.21MCYAD
6$103,547,438$76,550,313.71$17,539$370.97+$103.53MCYAD
7$404,404,397$293,608,638.27$19,143$375.96+$404.39MCYAD
8$1,504,383,912$1,071,671,207.21$20,863$380.42+$1504.36MCYAD
9$5,335,499,864$3,725,809,078.26$22,708$384.39+$5335.48MCYAD
10$18,058,595,107$12,349,610,253.13$24,685$387.88+$18058.57MCYAD

CYAD vs QSR: Complete Analysis 2026

CYADStock

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Full CYAD Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this CYAD vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYAD vs SCHDCYAD vs JEPICYAD vs OCYAD vs KOCYAD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.